The global controlled substance market was valued at US$ 91.2 billion in 2024 and is projected to reach US$ 169.8 billion by 2035, growing at a CAGR of 5.8% from 2025 to 2035. The market expansion is driven by rising prevalence of chronic pain, increasing incidence of neurological and psychiatric disorders, and growing demand for regulated pharmaceutical products used in pain management, anesthesia, and attention deficit disorders.

👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=25964

Market Overview

The market for controlled substances includes drugs and chemicals that are subject to strict regulations by the authorities due to their possible harmful use, addiction, or negative health effects. Medications that fall under the categories of opioids, stimulants, depressants, and partly hallucinogens are the most common ones in the treatment of chronic pain, anxiety, sleeping disorders, and attention-deficit disorders, among other diseases.

For instance, the World Health Organization (WHO) highlights that 2.6 Mn deaths per year were attributed to alcohol consumption, accounting for 4.7% of all deaths, and 0.6 Mn deaths to psychoactive drug use. Notably, 2 Mn of alcohol and 0.4 Mn of drug-attributable deaths were among men.

The demand for the product is caused by the rising influence of chronic and neurological diseases, the increasing availability of healthcare, and the progress made in drug formulations. However, these market dynamics are also significantly impacted by the worries about the misuse, dependence, and tough approval procedures that continue to be concerns in the pharmaceutical field.

Analysts’ Viewpoint

The global market for controlled drugs steadily expands with the main driver being the escalating cases of chronic pain, neurological disorders, and psychiatric conditions that need medications that are regulated by the authorities. Strict government regulations and necessary compliance requirements are a hurdles to manufacturers and distributors, the latter, however, it assure the safety of patients as well as a usage that is well controlled, which is very important as far as the credibility of the market is concerned.

Growth is being driven by increasing investment for research and development, the wide usage of telemedicine, and digital prescription monitoring. But the issue of drug addiction, as well as the stringent regulatory frameworks, continue to be significant influences on the market trend. The trend for such a market would most likely indicate the development of a more balanced approach with both greater access to patients and closer supervision to reduce drug misuse.

Analysis of Key Players

The competitive landscape is characterized by extensive investments in pain management therapies, central nervous system (CNS) treatments, abuse-deterrent technologies, and regulatory compliance programs.

Leading companies operating in the global controlled substance market include:

• UPM Pharmaceuticals
• Johnson & Johnson
• Merck & Co., Inc.
• AbbVie Inc
• Grünenthal
• Novartis AG
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Purdue Pharma L.P.
• AstraZeneca
• Sanofi
• Mallinckrodt plc
• Sun Pharmaceutical Industries Ltd.
• Lannett
• Teva Pharmaceutical Industries Ltd.
• Other Prominent Players

Strategic investments in abuse-resistant formulations, expanded manufacturing capabilities, and regulatory-compliant distribution systems remain key competitive strategies among market participants.

Recent Developments (2024–2025)

• In January 2025, Journavx (suzetrigine) was approved by the U.S. FDA. It is the first new non-opioid pain medication for almost 20 years. The medicine is aimed at relieving the pain of moderate-to-severe acute cases and, thus, is a better solution to the opioids that are characterized by no addiction risks.
• In May 2025, ProMed Pharma, a cdmo specialising in polymer-based drug-delivery systems, announced it has obtained registration from the Drug Enforcement Administration (DEA) to handle Schedule III controlled substances.
• In December 2024, the DEA announced that it had improved the Controlled Substance Ordering System (CSOS) to guarantee safe electronic ordering of Schedule I-V controlled substances. The update features a more convenient user registration and certificate administration via Login.gov.
• In May 2024, PharmaDrug,​ a Toronto-based specialty pharmaceutical company that focuses on controlled-substances, natural medicines, and previously approved drugs, announced that its wholly-owned subsidiary SecureDose had signed a Letter of Intent (LOI) with a Canadian licensed dealer of controlled drug substances (May 16, 2024) to start GMP manufacturing of a new biosynthetic formulation of pharmaceutical-grade ​cocaine.

👉 Discuss Implications for Your Industry Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=25964

Key Developments & Trends

• Abuse-Deterrent Formulations: Growing focus on reducing misuse and dependency risks.
• Digital Prescription Monitoring: Increasing implementation of electronic prescribing and tracking systems.
• Chronic Pain Management Growth: Rising demand for pain relief therapies among aging populations.
• Mental Health Treatment Expansion: Growing utilization of controlled medications for ADHD and psychiatric disorders.
• Advanced Drug Delivery Systems: Development of extended-release and targeted delivery formulations.

Challenges

• Stringent Regulatory Requirements: Complex compliance and reporting obligations for manufacturers and distributors.
• Risk of Substance Abuse: Ongoing concerns regarding misuse and dependency.
• Litigation and Legal Scrutiny: Increased legal oversight in opioid and controlled medication markets.
• Supply Chain Security: Ensuring secure transportation and storage of regulated substances.

Opportunities

• Abuse-Resistant Drug Development: Significant opportunity for safer formulations.
• Emerging Market Expansion: Increasing healthcare access driving prescription demand.
• Personalized Pain Management: Development of patient-specific treatment approaches.
• Digital Healthcare Integration: Enhanced monitoring and compliance through health technology platforms.

Market Segmentation

By Drug

• Opioids
• Codeine
• Morphine
• Fentanyl
• Hydrocodone
• Tramadol
• Oxycodone
• Others
• Stimulant
• Amphetamine
• Methylphenidate
• Dextroamphetamine
• Methamphetamine
• Modafinil
• Others
• Depressants
• Barbiturates
• Benzodiazepines
• Cannabinoids
• Others (Anabolic Steroids)

By Indication

• ADHD
• Pain Management
• Cough Suppression
• Anaesthesia
• Sleep disorder
• Seizure Control
• Muscle Relaxation
• Others (Chronic pain, Acute pain)

By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies

Conclusion

The controlled substance market remains a vital segment of the global pharmaceutical industry, supporting the treatment of chronic pain, neurological disorders, psychiatric conditions, and surgical care. Through 2035, advancements in abuse-deterrent technologies, digital prescription monitoring, and innovative drug delivery systems are expected to enhance patient safety and regulatory compliance. As healthcare systems continue balancing therapeutic necessity with responsible usage, controlled substances will remain essential to modern medical practice.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=25964&ltype=S

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com